Ligand Pharmaceuticals (LGND) Change in Accured Expenses (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Change in Accured Expenses data on file, last reported at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 226.29% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.7 million (down 18.2% YoY), and the FY2025 full-year result was $5.9 million, down 57.69% from the prior year.
• Change in Accured Expenses fell to $2.7 million in Q1 2026, from $7.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $11.3 million in Q4 2024 to a low of -$4.5 million in Q2 2023.
• A 5-year average of $850294.1 and a median of -$407000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 460.57% in 2022, while the deepest fall reached 676.17% in 2022.
• Tracing LGND's Change in Accured Expenses over 5 years: stood at -$2.9 million in 2022, then jumped by 193.94% to $2.8 million in 2023, then surged by 309.36% to $11.3 million in 2024, then slumped by 34.92% to $7.3 million in 2025, then plunged by 63.05% to $2.7 million in 2026.
• Business Quant data shows LGND's Change in Accured Expenses at $2.7 million in Q1 2026, $7.3 million in Q4 2025, and $1.1 million in Q3 2025.